Abstract
Apelin was identified as natural ligand for APJ, a G protein-coupled receptor. APJ is expressed in spinal cord and dorsal root ganglion. This study was designed to investigate the effects and mechanisms of intrathecally (i.t.) administered apelin-13 on nociceptive response in formalin test and tail-flick test. In formalin test, i.t. injection of apelin-13 (0.3—3 nmol/mouse) had no effect on the nociceptive response in either acute phase (0— 10 min) or interphase (10—20 min), but significantly produced hyperalgesic effect in late phase (20—30 min) at the dose of 3 nmol/mouse. The APJ receptor antagonist apelin-13(F13A) and GABAA receptor antagonist bicuculline methiodide, but not opioid receptor antagonist naloxone, significantly blocked the hyperalgesia caused by apelin-13 in late phase, indicating that i.t. apelin-13- induced hyperalgesia was mediated by APJ and GABAA receptor, rather than opioid receptor. However, in tail-flick test, i.t. injected apelin-13 (1 and 3 nmol/mouse) induced a significant antinociceptive effect, which was significantly antagonized by apelin-13(F13A) and naloxone, suggesting APJ and opioid receptor were involved in the antinociception of spinal apelin-13.
Keywords: Apelin-13, APJ, formalin test, GABA, mice, opioid, tail-flick test.
Protein & Peptide Letters
Title:Intrathecal Apelin-13 Produced Different Actions in Formalin Test and Tail-flick Test in Mice
Volume: 20 Issue: 8
Author(s): Shuang- Yu Lv, Yan Jie Yang, Shangyu Hong, Ning- Bo Wang, Yao- Jun Qin, Wei- Xin Li and Qiang Chen
Affiliation:
Keywords: Apelin-13, APJ, formalin test, GABA, mice, opioid, tail-flick test.
Abstract: Apelin was identified as natural ligand for APJ, a G protein-coupled receptor. APJ is expressed in spinal cord and dorsal root ganglion. This study was designed to investigate the effects and mechanisms of intrathecally (i.t.) administered apelin-13 on nociceptive response in formalin test and tail-flick test. In formalin test, i.t. injection of apelin-13 (0.3—3 nmol/mouse) had no effect on the nociceptive response in either acute phase (0— 10 min) or interphase (10—20 min), but significantly produced hyperalgesic effect in late phase (20—30 min) at the dose of 3 nmol/mouse. The APJ receptor antagonist apelin-13(F13A) and GABAA receptor antagonist bicuculline methiodide, but not opioid receptor antagonist naloxone, significantly blocked the hyperalgesia caused by apelin-13 in late phase, indicating that i.t. apelin-13- induced hyperalgesia was mediated by APJ and GABAA receptor, rather than opioid receptor. However, in tail-flick test, i.t. injected apelin-13 (1 and 3 nmol/mouse) induced a significant antinociceptive effect, which was significantly antagonized by apelin-13(F13A) and naloxone, suggesting APJ and opioid receptor were involved in the antinociception of spinal apelin-13.
Export Options
About this article
Cite this article as:
Lv Yu Shuang-, Yang Jie Yan, Hong Shangyu, Wang Bo Ning-, Qin Jun Yao-, Li Xin Wei- and Chen Qiang, Intrathecal Apelin-13 Produced Different Actions in Formalin Test and Tail-flick Test in Mice, Protein & Peptide Letters 2013; 20 (8) . https://dx.doi.org/10.2174/0929866511320080010
DOI https://dx.doi.org/10.2174/0929866511320080010 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Renal Complications of Fabry Disease
Current Pharmaceutical Design Gender Differences in Response to Therapy for Cardiovascular Diseases
Current Pharmacogenomics and Personalized Medicine Angiotensin Converting Enzyme (ACE) Inhibitory Peptides: Production and Implementation of Functional Food
Current Pharmaceutical Design Influence of Dietary Substances on Intestinal Drug Metabolism and Transport
Current Drug Metabolism Treating Cancer and No-Cancer Pain in Older and Oldest Old Patients
Current Pharmaceutical Design Vascular Risk Factors and Neurodegeneration in Ageing Related Dementias: Alzheimer’s Disease and Vascular Dementia
Current Alzheimer Research Hypersensitivity to Antineoplastic Agents
Current Pharmaceutical Design The Treatment of Painful Diabetic Neuropathy
Current Diabetes Reviews Recent Updates of Chemically Modified Electrodes in Pharmaceutical Analysis
Combinatorial Chemistry & High Throughput Screening N-Acetylcysteine and Other Preventive Measures for Contrast-Induced Nephropathy in the Intensive Care Unit
Current Medicinal Chemistry Cysteine-Rich Mini-Proteins in Human Biology
Current Topics in Medicinal Chemistry Beyond Rodent Models of Pain: Non-Human Primate Models for Evaluating Novel Analgesic Therapeutics and Elaborating Pain Mechanisms
CNS & Neurological Disorders - Drug Targets Endothelial Effects of Drugs Designed to Treat Erectile Dysfunction
Current Pharmaceutical Design Nanocrystalline ZnO: A Competent and Reusable Catalyst for the Preparation of Pharmacology Relevant Heterocycles in the Aqueous Medium
Current Green Chemistry Gemcitabine-Related Atrial Fibrillation: A Case Report and Review of the Literature
Current Drug Safety Brief Review of Polymorphic Drug-Metabolizing Enzymes in Japanese Populations: Development of a Higher-Throughput Genotyping Method and Proposed Applications
Drug Metabolism Letters Applications of Barton-McCombie Reaction in Total Syntheses
Current Organic Synthesis Update of Targeted Therapy-Induced Hypertension: Basics for Non-Oncology Providers
Current Hypertension Reviews Editorial (Hot Topic: Recent Advances in Neonatal Pharmacology)
Current Drug Metabolism Therapeutic Use of Nitric Oxide Scavengers in Shock and Sepsis
Current Pharmaceutical Design